• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24040 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease
2024     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Point-of-care ultrasound for the evaluation of pulmonary volume overload in an outpatient setting]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Chronic graft-versus-host disease; assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - iptacopan (paroxysmal nocturnal haemoglobinuria)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - epcoritamab (relapsed or refractory follicular lymphoma)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Odronextamab (relapsed or refractory follicular lymphoma)]
2024     Canary Health Service [Safety and efficacy of the use of compression garments in the treatment of lipedema]
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and white British people presenting to emergency services for injury: the stakeholder consultation
2024     Austrian Institute for Health Technology Assessment (AIHTA) Telehealth in diabetes – EU mapping and systematic evaluation of organisational aspects
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in dystonia, dyspareunia, and strabismus]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets]
2024     Gesundheit Osterreich GmbH (GOeG) [Long-term effectiveness of early interventions for children and adolescents with psychological stress]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]
2024     Scottish Health Technologies Group (SHTG) Digital fracture liaison service
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Rigid-platform (TEM/ TEO) or flexible-platform (TAMIS) endoscopic transanal surgery for the treatment of rectal lesions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polihexanide (Acanthamoeba keratitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (mucormycosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (aspergillosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Lorviqua (ALK+ NSCLC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Velexbru (primary CNS b-cell lymphoma)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Padcev (urothelial cancer)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Nubeqa (Prostate Cancer - mCSPC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Crysvita (XLH - x-linked hypophosphatemia)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Altuviiio lyophilized powder solution for IV injection]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (renal cell carcinoma - RCC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (malignant pleural mesothelioma - MPM)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (ESCC - first-line treatment)
2024     Center for Drug Evaluation (CDE) [HTA for Medical Device: Metallic biliary stents (Rapid HTA report)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous treatment for moderate to severe mitral valve insufficiency]
2024     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2024     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2023
2024     Institute for Clinical and Economic Review (ICER) Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024     Institute for Clinical and Economic Review (ICER) Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
2024     Institute for Clinical and Economic Review (ICER) Imetelstat for anemia in myelodysplastic syndrome: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Ensifentrine for the treatment of chronic obstructive pulmonary disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Midomafetamine-assisted psychotherapy for post-traumatic stress disorder
2024     Institute for Clinical and Economic Review (ICER) Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
2024     Institute for Clinical and Economic Review (ICER) KarXT for schizophrenia
2024     Institute for Clinical and Economic Review (ICER) Sotatercept for pulmonary arterial hypertension
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood determination of a panel of anti-tuberculosis drugs using a multiplex approach by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in the context of clinical pharmacometrics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clozapine blood level testing by immunoassay]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: helicobacter pylori - diagnosis, optimal treatment and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: confirmed chlamydia trachomatis or neisseria gonorrhoeae infection]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT5 phosphorylation status by flow cytometry]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT3 phosphorylation status by flow cytometry]
2024     Health Information and Quality Authority (HIQA) A summary of publicly-funded services for fertility preservation for medical reasons in selected countries
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of emergency departments with or without a co-located primary care driven urgent care center
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Umbilical cord clamping at one minute, allowing stem cell harvesting, compared with delayed cord clamping - infant and maternal outcomes
2024     Haute Autorite de sante (HAS) [Assessment of the endoscopic transluminal necrosectomy procedure in the treatment of acute necrotizing pancreatitis]
2024     Norwegian Institute of Public Health (NIPH) [Cost-effectiveness of robot assisted surgery for prostate cancer]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Stereotactic radiosurgery in benign tumors of the central nervous system]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: syndromic approach - pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: genital herpes - identification, diagnosis, optimal use of antivirals and follow-up]
2024     National Institute for Health and Care Excellence (NICE) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome. NICE diagnostics guidance 62
2024     National Institute for Health and Care Excellence (NICE) Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. NICE interventional procedures guidance 795
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound subthalamotomy for treating Parkinson's. NICE interventional procedures guidance 797
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's. NICE interventional procedures guidance 796
2024     National Institute for Health and Care Excellence (NICE) Bevacizumab gamma for treating wet age-related macular degeneration. NICE technology appraisal guidance 1022
2024     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021
2024     National Institute for Health and Care Excellence (NICE) Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal). NICE technology appraisal guidance 1024
2024     National Institute for Health and Care Excellence (NICE) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2024     National Institute for Health and Care Excellence (NICE) Ublituximab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 1025
2024     National Institute for Health and Care Excellence (NICE) Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2024     HTA Region Stockholm [Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction]
2024     HTA Region Stockholm [Benefits and harms of intra-articular corticosteroid injections for hip osteoarthritis]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood cortisol and dexamethasone measurements using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in the context of a dexamethasone suppression test]
2024     NIHR Health Technology Assessment programme Energetic activity for depression in young people aged 13–17 years: the READY feasibility RCT
2024     NIHR Health Services and Delivery Research programme A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study
2024     NIHR Health Services and Delivery Research programme Clinical and cost-effectiveness of first contact physiotherapy for musculoskeletal disorders in primary care: the FRONTIER, mixed method realist evaluation
2024     NIHR Health Technology Assessment programme Cervical ripening at home or in hospital during induction of labour: the CHOICE prospective cohort study, process evaluation and economic analysis
2024     NIHR Health and Social Care Delivery Program Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: medical imaging of the head]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to managing people with colorectal cancer]
2024     NIHR Health Services and Delivery Research programme Strengthening open disclosure in maternity services in the English NHS: the DISCERN realist evaluation study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: quantification of antipsychotics in serum using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – addendum to project H23-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – assessment according to §137h Social Code Book (SGB) V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Methods for determining the extent of added benefit - empirical data from dossier assessments]